This Pharmaceutical Company Completes 100 per cent Acquisition of Antibe Therapeutics for CAD 4.5 Million

With a PE ratio of 35.2x, the company trades at a premium compared to the industry PE of 28.9x. The company has ROCE of 17.3 per cent and ROE of 16.7 per cent.  

Sun Pharmaceutical Industries Limited has announced the completion of its 100% acquisition of Antibe Therapeutics Inc., a Canadian company, through its subsidiary TARO Pharmaceuticals Inc. The acquisition was finalized for a total consideration of CAD 4.5 million. This strategic move is part of Sun Pharma's ongoing efforts to expand its global footprint and enhance its product offerings. As a leading player in the pharmaceutical industry, Sun Pharma continues to focus on manufacturing, developing, and marketing a diverse range of branded and generic formulations, along with Active Pharma Ingredients (APIs). The company has a significant presence worldwide, with numerous manufacturing facilities and trading activities.

As of 18 March 2025, Sun Pharma's stock price stands at Rs 1726, with a market capitalization of Rs 4,09,338.54 crores. The stock has delivered a 3-year return of 87.32 per cent, showcasing its growth trajectory and appeal to investors. This acquisition further solidifies Sun Pharma's position in the global market, potentially opening new avenues for growth and development.

Sun Pharmaceutical Industries Ltd is a leading pharmaceutical company engaged in the manufacturing, development, and marketing of a wide array of branded and generic formulations, as well as Active Pharma Ingredients (APIs). With a robust global presence, the company operates multiple manufacturing facilities worldwide, supporting its extensive trading and related activities. Sun Pharma's strategic acquisitions and global operations continue to enhance its market position and drive its success in the pharmaceutical industry. The company has been maintaining a healthy dividend payout of 46.6 per cent.

In the Quarterly Results of Dec-24, the revenue stood at Rs 13,675.46 crore, reflecting a YoY growth of 10.46 per cent and a QoQ increase of 2.89 per cent from Rs 13,291.39 crore in Sep-24. The net profit for Dec-24 was Rs 2,903.38 crore, showing a YoY increase of 15.04 per cent but a QoQ decline of 4.50 per cent from Rs 3,040.16 crore in Sep-24. The net profit margin for Dec-24 was 21.23 per cent, compared to 22.87 per cent in Sep-24 and 20.38 per cent in Dec-23.

For the full-year FY24 results, the revenue stood at Rs 48,496.85 crore, reflecting a growth of 10.51 per cent from Rs 43,885.68 crore in FY23. The net profit for FY24 was Rs 11,433.74 crore, registering a growth of 8.42 per cent from Rs 8,783.21 crore in FY23. The net profit margin for FY24 stood at 18.11 per cent compared to 18.46 per cent in FY23.

As of December 2024, the shareholding pattern is as follows: Promoters hold 54.48 per cent, FIIs hold 18.04 per cent, DIIs hold 18.43 per cent, the government holds 0.11 per cent, and the public holds 8.92 per cent.

With a PE ratio of 35.2x, the company trades at a premium compared to the industry PE of 28.9x. The company has ROCE of 17.3 per cent and ROE of 16.7 per cent.  

Investors must keep this Large-Cap stock on their radar.

Disclaimer: The article is for informational purposes only and not investment advice.